Related Experiment Video

Updated: Oct 21, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma

Takayo Ota1, Aya Okabayashi2, Masahiro Fukuoka1

  • 1Department of Medical Oncology Izumi City General Hospital Izumi Japan.

Respirology Case Reports
|September 6, 2021
PubMed

Insights

BRAF V600E-mutated lung cancer, often aggressive and resistant to chemotherapy, can be effectively treated with BRAF/MEK inhibitors. This combination therapy rapidly improved a patient

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • V-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto-oncogene regulating cell proliferation and survival.
  • BRAF V600E mutations confer aggressive characteristics and chemoresistance in lung cancer.
  • BRAF inhibitor dabrafenib plus MEK inhibitor trametinib is standard for BRAF V600E-mutated lung cancer.

Observation:

  • A patient with advanced BRAF V600E-mutated lung adenocarcinoma presented with respiratory distress.
  • The patient's condition indicated rapid cancer deterioration.

Findings:

  • The patient received combination BRAF/MEK inhibitor therapy.
  • A significant and rapid tumor response was observed.
  • Patient symptoms improved within two weeks of treatment.

Implications:

  • BRAF/MEK inhibitors demonstrate efficacy in BRAF-mutated lung cancer, even in critical conditions.
  • This highlights the therapeutic potential of targeted therapies in advanced lung cancer.
  • Rapid symptom improvement underscores the clinical benefit of these targeted agents.
Keywords:
BRAF mutationBRAF/MEK inhibitorslung adenocarcinoma

More Related Videos

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K